Citadel Advisors’s SOPHiA GENETICS SOPH Stock Holding History
Bought
Maintained
Sold
Other funds holding SOPH
GIM
ACM
ACM
RA
BPC
AIC
SCM
SAM
Citadel Advisors's SOPH Position: Q2 2026 in Review
Citadel Advisors opened a new position in SOPHiA GENETICS (SOPH) in Q2 2026: 38,497 shares worth $222K. The stake represents ﹤0.01% of the portfolio and ranks #11822 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SOPH as recently as Q3 2025.
Citadel Advisors first reported a position in SOPH in Q4 2021 and has held it in 13 quarters since. The position peaked at $334K in Q1 2023. 71 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.
- Citadel Advisors held 38,497 shares of SOPHiA GENETICS worth $222K as of Q2 2026.
- SOPHiA GENETICS was a new Citadel Advisors position in Q2 2026.
- SOPHiA GENETICS made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11822 holding.
- Citadel Advisors first reported a position in SOPHiA GENETICS in Q4 2021 and has held it in 13 quarters since.
- Citadel Advisors's SOPHiA GENETICS position peaked at $334K in Q1 2023.
- 71 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.